(Q30580553)

22 September 2017

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer (English)

1 reference

22 September 2017

1 reference

13

Eric Solary

0 references

Fabrice André

12

Fabrice André

0 references

Jean-Charles Soria

28

Jean-Charles Soria

0 references

Gwénaël Le Teuff

26

Gwénaël Le Teuff

1 reference

22 September 2017

Jean-Pierre Pignon

3

0 references

Ming-Sound Tsao

Ming-Sound Tsao

5

0 references

Elisabeth Brambilla

27

Elisabeth Brambilla

1 reference

22 September 2017

8

Jean-Yves Douillard

1 reference

22 September 2017

23

Thierry Le Chevalier

1 reference

22 September 2017

Luc Friboulet

1

1 reference

22 September 2017

Ken André Olaussen

2

1 reference

22 September 2017

Frances A Shepherd

4

1 reference

22 September 2017

Stephen Graziano

6

1 reference

22 September 2017

Robert Kratzke

7

1 reference

22 September 2017

Lesley Seymour

9

1 reference

22 September 2017

Robert Pirker

10

1 reference

22 September 2017

Martin Filipits

11

1 reference

22 September 2017

Florence Ponsonnailles

14

1 reference

22 September 2017

Angélique Robin

15

1 reference

22 September 2017

Annabelle Stoclin

16

1 reference

22 September 2017

Nicolas Dorvault

17

1 reference

22 September 2017

Frédéric Commo

18

1 reference

22 September 2017

Julien Adam

19

1 reference

22 September 2017

Elsa Vanhecke

20

1 reference

22 September 2017

Patrick Saulnier

21

1 reference

22 September 2017

Jürgen Thomale

22

1 reference

22 September 2017

Ariane Dunant

24

1 reference

22 September 2017

Vanessa Rousseau

25

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

The New England Journal of Medicine

22 September 2017

1 reference

22 September 2017

368

1 reference

22 September 2017

12

1 reference

22 September 2017

1101-1110

1 reference

Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Mutational analysis of the human nucleotide excision repair gene ERCC1

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4054818

Expression of ERCC1 and Class III β-Tubulin in Resected Non-Small Cell Lung Cancer and its Correlation with Platinum-Based Adjuvant Chemotherapy

26 November 2018

1 reference

12 December 2020

Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients

1 reference

12 December 2020

ERCC1-specific immunostaining in non-small-cell lung cancer

1 reference

12 December 2020

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

12 December 2020

Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype

1 reference

12 December 2020

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

1 reference

12 December 2020

Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma

1 reference

12 December 2020

Validation of ERCC1-XPF immunodetection--letter

1 reference

12 December 2020

ERCC1 and non-small-cell lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1214271

1 reference

22 September 2017

1 reference

22 September 2017

PubMed publication ID

23514287

1 reference